Aeterna Zentaris Inc (AEZS) - Financial and Strategic SWOT Analysis Review

September 2021 | 56 pages | ID: A923627EAE5EN
GlobalData

Abstracts

Aeterna Zentaris Inc (AEZS) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and the potential opportunities and threats. The profile helps you formulate strategies that augment your business by enabling you to understand your partners, customers and competitors better.

The profile contains critical company information including:

• Business description – A detailed description of the company’s operations and business divisions.
• Corporate strategy – Analyst’s summarization of the company’s business strategy.
• SWOT Analysis – A detailed analysis of the company’s strengths, weakness, opportunities and threats.
• Company history – Progression of key events associated with the company.
• Major products and services – A list of major products, services and brands of the company.
• Key competitors – A list of key competitors to the company.
• Key employees – A list of the key executives of the company.
• Executive biographies – A brief summary of the executives’ employment history.
• Key operational heads – A list of personnel heading key departments/functions.
• Important locations and subsidiaries – A list and contact details of key locations and subsidiaries of the company.
• Detailed financial ratios for the past five years – The latest financial ratios derived from the annual financial statements published by the company with 5 years history.
• Interim ratios for the last five interim periods – The latest financial ratios derived from the quarterly/semi-annual financial statements published by the company for 5 interims history.

Highlights

Aeterna Zentaris Inc (Aeterna Zentaris) is a specialty biopharmaceutical company that focuses on the development and commercialization of novel pharmaceutical therapies for the treatment of unmet medical needs. The company’s lead product, Macrilen (macimorelin), a ghrelin receptor agonist and orally active small molecule is used for the treatment of patients with adult growth hormone deficiency (AGHD). The company has operations in the US, Canada, Germany and has license agreements for its products in Ireland, China, British Virgin Islands, Denmark, and other countries. Aeterna Zentaris is headquartered in Summerville, South Carolina, the US.

Aeterna Zentaris Inc Key Recent Developments

Aug 04,2021: Aeterna Zentaris Reports Second Quarter 2021 Financial Results and Provides Pipeline Program Updates
Jun 07,2021: Aeterna Zentaris engages Dr. Michael Levy to support development of autoimmune and inflammatory CNS disorders programs
May 05,2021: Aeterna Zentaris Reports First Quarter 2021 Financial Results and Provides Pipeline Program Updates
May 05,2021: Aeterna Zentaris Announces Results of 2021 Annual Meeting of Shareholders
May 03,2021: Aeterna Zentaris Appoints Michael Teifel, Ph.D. as Senior Vice President, Non-Clinical Development and Chief Scientific Officer

Key benefits of buying this profile include:

You get detailed information about the company and its operations to identify potential customers and suppliers.

• The profile analyzes the company’s business structure, operations, major products and services, prospects, locations and subsidiaries, key executives and their biographies and key competitors.

Understand and respond to your competitors’ business structure and strategies, and capitalize on their weaknesses. Stay up to date on the major developments affecting the company.

• The company’s core strengths and weaknesses and areas of development or decline are analyzed and presented in the profile objectively. Recent developments in the company covered in the profile help you track important events.

Equip yourself with information that enables you to sharpen your strategies and transform your operations profitably.

• Opportunities that the company can explore and exploit are sized up and its growth potential assessed in the profile. Competitive and/or technological threats are highlighted.

Scout for potential investments and acquisition targets, with detailed insight into the companies’ strategic, financial and operational performance.

• Financial ratio presented for major public companies in the profile include the revenue trends, profitability, growth, margins and returns, liquidity and leverage, financial position and efficiency ratios.

Gain key insights into the company for academic or business research.

• Key elements such as SWOT analysis, corporate strategy and financial ratios and charts are incorporated in the profile to assist your academic or business research needs.

Note: Some sections may be missing if data is unavailable for the company

Contents

SECTION 1 - ABOUT THE COMPANY

Aeterna Zentaris Inc - Key Facts
Aeterna Zentaris Inc - Key Employees
Aeterna Zentaris Inc - Key Employee Biographies
Aeterna Zentaris Inc - Major Products and Services
Aeterna Zentaris Inc - History
Aeterna Zentaris Inc - Company Statement
Aeterna Zentaris Inc - Locations And Subsidiaries
Head Office
Other Locations & Subsidiaries

SECTION 2 – COMPANY ANALYSIS

Company Overview
Aeterna Zentaris Inc - Business Description
Product Category: License Fee
Performance
Product Category: Product Sales
Performance
Product Category: Royalty Income
Performance
Product Category: Supply Chain
Performance
Geographical Segment: British Virgin Islands
Performance
Geographical Segment: China
Performance
Geographical Segment: Denmark
Performance
Geographical Segment: Ireland
Performance
Geographical Segment: Others
Performance
Geographical Segment: Switzerland
Performance
Geographical Segment: United States
Performance
R&D Overview
Aeterna Zentaris Inc - Corporate Strategy
Aeterna Zentaris Inc - SWOT Analysis
SWOT Analysis - Overview
Aeterna Zentaris Inc - Strengths
Aeterna Zentaris Inc - Weaknesses
Aeterna Zentaris Inc - Opportunities
Aeterna Zentaris Inc - Threats
Aeterna Zentaris Inc - Key Competitors

SECTION 3 – COMPANY FINANCIAL RATIOS

Financial Ratios - Capital Market Ratios
Financial Ratios - Annual Ratios
Performance Chart
Financial Performance
Financial Ratios - Interim Ratios
Financial Ratios - Ratio Charts

SECTION 4 – COMPANY’S LIFESCIENCES FINANCIAL DEALS AND ALLIANCES

Aeterna Zentaris Inc, Pharmaceuticals & Healthcare, Deals By Year, 2015 to YTD 2021
Aeterna Zentaris Inc, Pharmaceuticals & Healthcare, Deals By Type, 2015 to YTD 2021
Aeterna Zentaris Inc, Recent Deals Summary

SECTION 5 – COMPANY’S RECENT DEVELOPMENTS

Aug 04, 2021: Aeterna Zentaris Reports Second Quarter 2021 Financial Results and Provides Pipeline Program Updates
Jun 07, 2021: Aeterna Zentaris engages Dr. Michael Levy to support development of autoimmune and inflammatory CNS disorders programs
May 05, 2021: Aeterna Zentaris Reports First Quarter 2021 Financial Results and Provides Pipeline Program Updates
May 05, 2021: Aeterna Zentaris Announces Results of 2021 Annual Meeting of Shareholders
May 03, 2021: Aeterna Zentaris Appoints Michael Teifel, Ph.D. as Senior Vice President, Non-Clinical Development and Chief Scientific Officer
Apr 28, 2021: Aeterna Zentaris Announces Virtual 2021 Annual Meeting of Shareholders
Mar 25, 2021: Aeterna Zentaris Reports Fourth Quarter and Full Year 2020 Financial Results
Mar 11, 2021: Aeterna Zentaris continues to demonstrate pipeline expansion – announces the initiation of its preclinical program for the potential treatment of primary hypoparathyroidism
Feb 24, 2021: Aeterna Zentaris to Present at the H.C. Wainwright Global Life Sciences Conference
Feb 03, 2021: Aeterna Zentaris signs agreement to evaluate oral Covid-19 vaccine

SECTION 6 – APPENDIX

Methodology
Ratio Definitions
About GlobalData
Contact Us
Disclaimer

List Of Tables

LIST OF TABLES

Aeterna Zentaris Inc, Key Facts
Aeterna Zentaris Inc, Key Employees
Aeterna Zentaris Inc, Key Employee Biographies
Aeterna Zentaris Inc, Major Products and Services
Aeterna Zentaris Inc, History
Aeterna Zentaris Inc, Subsidiaries
Aeterna Zentaris Inc, Key Competitors
Aeterna Zentaris Inc, Ratios based on current share price
Aeterna Zentaris Inc, Annual Ratios
Aeterna Zentaris Inc, Annual Ratios (Cont...1)
Aeterna Zentaris Inc, Annual Ratios (Cont...2)
Aeterna Zentaris Inc, Interim Ratios
Aeterna Zentaris Inc, Pharmaceuticals & Healthcare, Deals By Year, 2015 to YTD 2021
Aeterna Zentaris Inc, Pharmaceuticals & Healthcare, Deals By Type, 2015 to YTD 2021
Aeterna Zentaris Inc, Recent Deals Summary
Currency Codes
Capital Market Ratios
Equity Ratios
Profitability Ratios
Cost Ratios
Liquidity Ratios
Leverage Ratios
Efficiency Ratios

List Of Figures

LIST OF FIGURES

Aeterna Zentaris Inc, Performance Chart (2016 - 2020)
Aeterna Zentaris Inc, Ratio Charts
Aeterna Zentaris Inc, Pharmaceuticals & Healthcare, Deals By Year, 2015 to YTD 2021
Aeterna Zentaris Inc, Pharmaceuticals & Healthcare, Deals by Type, 2015 to YTD 2021